Acer Medical (6857) H2 2024 earnings summary

Executive summary

• Revenue increased 83% year-over-year to NT$50,157K for the year ended December 31, 2024, driven by both smart healthcare and health product sales.

• Net loss narrowed to NT$27,364K from NT$38,181K year-over-year, reflecting improved gross margin and higher sales, despite increased operating expenses.

• Acquisition of 100% equity in Acer Health Co., Ltd. completed in January 2024 for NT$2,500K, expanding the health product segment.

Financial highlights

• Operating loss improved to NT$30,196K from NT$41,160K year-over-year.

• Gross margin rose to 63% from 47% year-over-year, reflecting better product mix and cost control.

• Basic and diluted loss per share improved to NT$1.80 from NT$2.51 year-over-year.

• Cash and cash equivalents at year-end were NT$202,777K, down from NT$220,026K.

Outlook and guidance

• Adoption of new IFRS standards is not expected to cause significant changes to accounting policies.

• Management continues to focus on optimizing capital structure and ensuring sufficient resources for future operations.